{"title":"天然苯酚氨基甲酸酯:选择性 BuChE/FAAH 双抑制剂在阿尔茨海默病小鼠模型中显示出神经保护作用","authors":"Kuanrong Rong, Ziyun Li, Xiaoming Wu, Shan Gao, Jie Zhao, Jing Yang, Xiaorui Jiang, Jing Zhang, Wenjian Tang","doi":"10.1016/j.ejmech.2024.117003","DOIUrl":null,"url":null,"abstract":"FAAH inhibition can indirectly enhance endocannabinoid signaling to therapeutic levels, effectively preventing or slowing its progression of Alzheimer’s disease (AD). Hence, the search for effective dual FAAH/cholinesterase inhibitors is considerable need for disease-modifying therapies. To this aim, we designed, synthesized, and tested three series of natural phenol carbamates. The majority of carbamates proved to be potent on a single target, amongst them, compound <strong>D12</strong> containing paeonol motif was identified as an effective dual BuChE/FAAH inhibitor, with well-balanced nanomolar activity (IC<sub>50</sub> = 81 and 400 nM for <em>h</em>BuChE and <em>h</em>FFAH, respectively). <strong>D12</strong> possessed BBB penetrating ability, benign safety, neuroprotection and pseudo-irreversible BuChE inhibition (<em>K</em><sub>d</sub> = 2.11 μM, <em>k</em><sub>2</sub> = 2.27 min<sup>-1</sup>), showing good drug-like properties. <strong>D12</strong> also modulated the BV2 microglial polarization to inhibit neuroinflammation. <em>In vivo</em> study verified that <strong>D12</strong> improved A<em>β</em><sub>1-41</sub>-induced learning impairments in AD mouse model for both short- and long-term memory responses. Thus, the dual activity of <strong>D12</strong> could lead to a potentially more effective treatment for the counteraction of AD progression.","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":6.0000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Natural phenol carbamates: Selective BuChE/FAAH dual inhibitors show neuroprotection in an Alzheimer’s disease mouse model\",\"authors\":\"Kuanrong Rong, Ziyun Li, Xiaoming Wu, Shan Gao, Jie Zhao, Jing Yang, Xiaorui Jiang, Jing Zhang, Wenjian Tang\",\"doi\":\"10.1016/j.ejmech.2024.117003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"FAAH inhibition can indirectly enhance endocannabinoid signaling to therapeutic levels, effectively preventing or slowing its progression of Alzheimer’s disease (AD). Hence, the search for effective dual FAAH/cholinesterase inhibitors is considerable need for disease-modifying therapies. To this aim, we designed, synthesized, and tested three series of natural phenol carbamates. The majority of carbamates proved to be potent on a single target, amongst them, compound <strong>D12</strong> containing paeonol motif was identified as an effective dual BuChE/FAAH inhibitor, with well-balanced nanomolar activity (IC<sub>50</sub> = 81 and 400 nM for <em>h</em>BuChE and <em>h</em>FFAH, respectively). <strong>D12</strong> possessed BBB penetrating ability, benign safety, neuroprotection and pseudo-irreversible BuChE inhibition (<em>K</em><sub>d</sub> = 2.11 μM, <em>k</em><sub>2</sub> = 2.27 min<sup>-1</sup>), showing good drug-like properties. <strong>D12</strong> also modulated the BV2 microglial polarization to inhibit neuroinflammation. <em>In vivo</em> study verified that <strong>D12</strong> improved A<em>β</em><sub>1-41</sub>-induced learning impairments in AD mouse model for both short- and long-term memory responses. Thus, the dual activity of <strong>D12</strong> could lead to a potentially more effective treatment for the counteraction of AD progression.\",\"PeriodicalId\":314,\"journal\":{\"name\":\"European Journal of Medicinal Chemistry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2024-10-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ejmech.2024.117003\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ejmech.2024.117003","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Natural phenol carbamates: Selective BuChE/FAAH dual inhibitors show neuroprotection in an Alzheimer’s disease mouse model
FAAH inhibition can indirectly enhance endocannabinoid signaling to therapeutic levels, effectively preventing or slowing its progression of Alzheimer’s disease (AD). Hence, the search for effective dual FAAH/cholinesterase inhibitors is considerable need for disease-modifying therapies. To this aim, we designed, synthesized, and tested three series of natural phenol carbamates. The majority of carbamates proved to be potent on a single target, amongst them, compound D12 containing paeonol motif was identified as an effective dual BuChE/FAAH inhibitor, with well-balanced nanomolar activity (IC50 = 81 and 400 nM for hBuChE and hFFAH, respectively). D12 possessed BBB penetrating ability, benign safety, neuroprotection and pseudo-irreversible BuChE inhibition (Kd = 2.11 μM, k2 = 2.27 min-1), showing good drug-like properties. D12 also modulated the BV2 microglial polarization to inhibit neuroinflammation. In vivo study verified that D12 improved Aβ1-41-induced learning impairments in AD mouse model for both short- and long-term memory responses. Thus, the dual activity of D12 could lead to a potentially more effective treatment for the counteraction of AD progression.
期刊介绍:
The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers.
A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.